Form 4: Interpace Biosciences President Receives Stock Grant
Insider Transaction (Form 4)
Thomas W. Burnell, CEO, President & Chairman and a Director of Interpace Biosciences, Inc., reported multiple transactions in common stock on August 20, 2026.
Summary
- Option exercise/conversion: acquired 1,966,763 Common Stock on August 20, 2026; holds 2,037,645 after (Direct).
- Tax/exercise-price withholding: disposed of 581,718 Common Stock at $1.61 ($936,566) on August 20, 2026; holds 1,455,927 after (Direct).
- Grant/award: acquired 1,966,763 Restricted Stock Units on August 20, 2026; holds 1,966,763 after (Direct).
- Option exercise/conversion: disposed of 1,966,763 Restricted Stock Units on August 20, 2026 (Direct).
- Grant/award: acquired 554,018 Stock Option (right to buy) on August 20, 2026; holds 554,018 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Thomas W. Burnell — Director, Officer (CEO, President & Chairman)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-20 | Option exercise/conversion | Common Stock | 1,966,763 | — | — | 2,037,645 |
| 2026-08-20 | Tax/exercise-price withholding | Common Stock | 581,718 | $2 | $936.6K | 1,455,927 |
| 2026-08-20 | Grant/award | Restricted Stock Units | 1,966,763 | — | — | 1,966,763 |
| 2026-08-20 | Option exercise/conversion | Restricted Stock Units | 1,966,763 | — | — | 0 |
| 2026-08-20 | Grant/award | Stock Option (right to buy) | 554,018 | — | — | 554,018 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-20 | Option exercise/conversion (1,966,763 shares) |
| 2026-08-20 | Tax/exercise-price withholding (581,718 shares) |
| 2026-08-20 | Grant/award (1,966,763 shares) |
| 2026-08-20 | Option exercise/conversion (1,966,763 shares) |
| 2026-08-20 | Grant/award (554,018 shares) |
Keywords
insider transaction, Form 4, IDXG, INTERPACE BIOSCIENCES, INC., neutral, Thomas W. Burnell
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.